Jeremy Lipshutz, MD
Interventional Pain Medicine · Las Vegas, NVNPI 1679675060
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,092 of the $13,038 with a category attached, or 69.7%. 35 manufacturers reported payments, led by Saluda Medical Americas, Inc. at 27.8% of the total. Reporting peaked in 2023 at $4,713 and has fallen 78.4% since, to $1,017 in 2025.
Across 230 payments — averaging $56.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$4K
- Medtronic$2K
- Nevro Corp.$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Biotronik NRO, Inc.$724
- Abbott$661
- plus $2K from 29 others
Across 1 payment — averaging $410.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$410
What the payments were for
- Consulting fees$1,2009%
- Travel & lodging$2,74621%
- Food & beverage$9,09270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Saluda Medical Americas, Inc. | 7 | $3,628 |
| Medtronic(2 entities) | 55 | $2,446 |
| Nevro Corp. | 26 | $1,962 |
| Biohaven Pharmaceuticals, Inc. | 3 | $1,227 |
| Biotronik NRO, Inc. | 19 | $724 |
| Abbott | 14 | $661 |
| Boston Scientific | 9 | $325 |
| Pfizer | 29 | $308 |
| Nutech Spine, Inc. | 1 | $242 |
| Globus Medical | 3 | $189 |
| Vertiflex, Inc. | 4 | $156 |
| Scilex Pharmaceuticals Inc. | 10 | $139 |
| Lilly USA, LLC | 3 | $114 |
| Biodelivery Sciences International, Inc. | 7 | $108 |
| Novo Nordisk | 5 | $104 |
| Collegium Pharmaceutical, Inc. | 5 | $77 |
| Tersera Therapeutics LLC | 4 | $69 |
| Spinal Simplicity, LLC | 1 | $60 |
| Linvatec Corporation | 1 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Almatica Pharma LLC | 2 | $49 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Forte Bio-pharma LLC | 1 | $31 |
| AbbVie | 2 | $28 |
| Bioventus LLC | 1 | $26 |
| Shionogi Inc | 2 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Foundation Fusion Solutions, LLC | 1 | $23 |
| Si-bone, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| GRT US Holding, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke SCS$3,437
- NURTEC ODT$1,200
- Omnia$1,127
- INTELLIS ADAPTIVESTIM$784
- MYSTIM$548
- Senza$538
- Prospera$290
- PROCLAIM$267
- SiFix$242
- INTELLIS$161
- KYPHON Balloon Kyphoplasty$128
- Proclaim Family of SCS IPGs$126
- Superion ISS$106
- GENERAL PAIN MANAGEMENT$106
How this compares
$13,038 in reported general payments places this provider in the 80th percentile of 32 interventional pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 120 | $1,988 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 61 | $1,813 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 59 | $1,604 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $1,320 |
| Oxycodone Hcl | 48 | $895 |
| Pregabalin | 32 | $773 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $517 |
| Tizanidine Hcl | 28 | $212 |
| Duloxetine Hcl | 24 | $134 |
| Cyclobenzaprine Hcl | 12 | $106 |
| Meloxicam | 20 | $45 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Las Vegas
- Adam AntflickLas Vegas$26K
- Stephen GephardtLas Vegas$14K
- Denys GoloshchapovLas Vegas$11K
- Edson ErkulvrawatrLas Vegas$6K
- Alafuro OrueneLas Vegas$6K
- Dolue EzeanolueLas Vegas$5K
- Katherine TravnicekLas Vegas$5K
- Godwin MadukaLas Vegas$4K
- Daniel BurkheadLas Vegas$4K
- Haroon AndarLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.